Slayback Pharma Announces $60 Million in New Financing by KKR
January 5, 2017
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170105005474/en/
Slayback is focused on expanding access to affordable health care. Since
early 2011, Slayback has filed, through its out-licensing partners,
numerous Abbreviated New Drug Applications (ANDAs) and 505(b)(2)
applications with the
“In addition to being a highly regarded long-term capital partner, KKR
with its rich legacy in the pharmaceutical space and its experience in
scaling businesses will help Slayback achieve the next level of growth,”
said CEO
As part of the transaction,
For KKR, the investment is part of the firm’s health care growth equity
strategy, which is focused on high-growth companies for which KKR can be
a unique partner in helping reach scale. The investment in Slayback
builds upon KKR’s experience in the pharmaceutical value chain,
including investments in Jazz Pharmaceuticals,
ABOUT
Slayback is a
ABOUT KKR
KKR is a leading global investment firm that manages investments across
multiple asset classes including private equity, energy, infrastructure,
real estate, credit, and hedge funds. KKR aims to generate attractive
investment returns by following a patient and disciplined investment
approach, employing world‐class people, and driving growth and value
creation at the asset level. KKR invests its own capital alongside its
partners’ capital and brings opportunities to others through its capital
markets business. References to KKR’s investments may include the
activities of its sponsored funds. For additional information about
View source version on businesswire.com: http://www.businesswire.com/news/home/20170105005474/en/
KKR
212-230-9722
media@kkr.com
Source:
Back to Press Releases
Media Contacts
Americas
Miles Radcliffe-Trenner
Telephone: +1 (212) 750-8300
Email: media@kkr.com
Investor Relations
Craig Larson
Telephone: +1 (877) 610-4910
Outside US: +1 (212) 230-9410
Facsimile: +1 (212) 750-0003
Email: Investor-Relations@kkr.com